Syndax Pharmaceuticals, Inc. (SNDX)
$13.95-15.71%Close
SELLCRISIS · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.2B
- Beta
- 0.37
- P/E (TTM)
- -5.54
- Short % float
- 22.91%
- Days to cover
- 8.5
- SI change
- -11.7%
- 1W
- -19.69%
- 1M
- -23.98%
- vs SPY 1W
- -19.55%
- vs SPY 1M
- -26.48%
Industry peers
FMP comparable companies · ranked by market cap
- RCUSSELLArcus Biosciences, Inc.$2.8BCRISISQ 17$22.51-7.52%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.13-0.14%
- ZYMESELLZymeworks Inc.$1.8BBEARQ 12$25.07-1.03%
- XNCRSELLXencor, Inc.$1.7BRECOVERYQ 15$23.52-6.07%
- NUVBSELLNuvation Bio Inc.$1.6BCRISISQ 4$4.72-3.67%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.31-4.23%
- REPLSELLReplimune Group, Inc.$1.0BCRISISQ 13$12.11-7.35%
- CTMXSELLCytomX Therapeutics, Inc.$506MCRISISQ 6$2.33-3.72%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 0
- GROWTH
- 27
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-223.8%
REV YoY-
ROE-372.9%
EPS YoY-
ROA-31.4%
GROSS97
OP-77
NET-88
[VALUATION]
P/E TTM-5.54
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B82.22
P/FCF-
EV/EBITDA-11.01
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3903.45
ALTMAN Z-
CURR RATIO6.77
ND/EBITDA-
BETA0.37
Company news
FAQ
- What is LOPJLB’s current signal on SNDX?
- LOPJLB’s latest quantitative signal on Syndax Pharmaceuticals, Inc. (SNDX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SNDX in?
- Syndax Pharmaceuticals, Inc. (SNDX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Syndax Pharmaceuticals, Inc. (SNDX) do?
- Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukem…